In addition, it has been recently demonstrated that a decreased H3K27me3 and increased H3K4me3 histone profile at gene promoter sequences of the Mesenchyme Homeobox-2 (MEOX2), HDAC9, and TWIST1 coding genes, as well additional genetical aberrations under aberrant epigenetic mechanisms, are associated or probably involved in poor clinical outcomes and lower survival rates, as well as involved in cancer-drug resistance mechanisms in NSCLC patients. The gene discussed is MEOX2; the disease is cancer.